botulinum toxin
Scope
Date
~
-
Bio & Pharma
Daewoong wins permission for Nabota in Argentina
South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...
Jul 15, 2024 (Gmt+09:00)
-
Bio & Pharma
Medytox to supply $73 mn botulinum toxin to Brazilian firm
South Korea's biopharmaceutical firm Medytox Inc. announced on Tuesday that it signed a contract with Brazilian pharmaceutical company Blau Farmaceu...
Mar 26, 2024 (Gmt+09:00)
-
Bio & Pharma
Medytox to enter China’s botulinum toxin market with Newlux
South Korean pharmaceutical company Medytox Inc. on Tuesday announced its plan to enter the Chinese market for botulinum toxins (BTX) with its cut...
Oct 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Hugel resubmits application to FDA for botulinum toxin product
South Korea's biopharmaceutical company Hugel Inc., announced on Friday that it has resubmitted applications to the US Food and Drug Administration ...
Sep 01, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong's Nabota exceeds 600,000 customers in US
South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...
Jul 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma to build third botulinum toxin plant for $746 mn
South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cos...
May 03, 2023 (Gmt+09:00)
-
Beauty & Cosmetics
Botulinum toxin resistance emerges as key factor for safe use
As demand for botulinum toxin for aesthetic purposes is globally increasing, safe use of the drug has emerged as one of the most important issues in...
Apr 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong’s Nabota expands into Germany, Austria
South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...
Mar 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Dubai delegation conducts due diligence on Medytox's plant in Korea
South Korea's biopharmaceutical firm Medytox Inc. said on Monday that a high-level delegation led by Dubai Science Park (DSP) under Dubai's state-ow...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
Jetema applies to test its botulinum toxin in US from July
South Korea's bio-esthetic pharmaceutical company Jetema Co. will hold clinical trials in the US to advance to the American market, the world's bigg...
Feb 27, 2023 (Gmt+09:00)
-
Bio & Pharma
US calls on 2 S.Korean pharmaceutical companies for swift end to legal battle
Following its lawsuit against Daewoong Pharmaceutical, South Korea's Medytox Inc. is waging an all-out legal war against domestic counterpart Hugel ...
Feb 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect
Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wri...
Feb 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma's botulinum toxin Nabota wins approval from Australia
Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Ja...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Medytox to build plant for finished toxin products in Dubai
South Korea's biopharmaceutical company Medytox Inc. will build a plant for finished products containing botulinum toxin in the United Arab Emirates...
Jan 17, 2023 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand